Urothelial carcinoma treatment: the future
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, reviews treatment options for bladder cancer. She highlights how MVAC is still used today, with clinical trials failing to ide...
Author: VJHemOnc
Added: 08/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Urothelial Carcinoma Abstracts | Enfortumab, Erdafitinib were Effective Based on Data
Nataliya Mar, MD, UC Irvine Health, shares her Urothelial Carcinoma Abstracts | Enfortumab, Erdafitinib were Effective Based on Data at MOASC 2018
Author: moasc
Added: 08/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Abstracts were Metastatic Genitourinary Malignancies | Mix of Urothelial Carcinoma, Prostate Cancer, & RCC
Nataliya Mar, MD, UC Irvine Health, shares her Abstracts were Metastatic Genitourinary Malignancies | Mix of Urothelial Carcinoma, Prostate Cancer, & RCC at MOASC 2018
Author: moasc
Added: 08/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 14, 2018 Category: Cancer & Oncology Source Type: podcasts
JAVELIN Merkel 200: avelumab for metastatic Merkel cell carcinoma
Patients with metastatic Merkel cell carcinoma (MCC) that does not respond to chemotherapy have a very poor survival rate after 1-2 years, representing a great unmet need. Here, Paul Nghiem, MD, PhD, ...
Author: VJOncology
Added: 08/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 13, 2018 Category: Cancer & Oncology Source Type: podcasts
Chemotherapy vs. immunotherapy for the treatment of Merkel cell carcinoma
In this interview, Paul Nghiem, MD, PhD, from the University of Washington, Seattle, WA, discusses the results of the Phase II trial investigating pembrolizumab as a first-line treatment for advanced ...
Author: VJOncology
Added: 08/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 13, 2018 Category: Cancer & Oncology Source Type: podcasts
Pembrolizumab in First Line Clear Cell RCC & amp; the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients with metastatic clear cell renal cell carcinoma and the implications for...
Author: BeaconMedIC
Added: 08/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 13, 2018 Category: Cancer & Oncology Source Type: podcasts
Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)
Dr. Daniel Goldstein summarizes the findings of a randomized trial assessing the benefit of adjuvant sunitinib following resection of oligometastatic disease in patients with renal cell carcinoma (RCC...
Author: BeaconMedIC
Added: 08/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051)
Dr. Daniel Goldstein reviews the key data and limitations from the CARMENA trial that re-evaluated the role of nephrectomy in metastatic renal cell carcinoma (RCC), providing insight into how the data...
Author: BeaconMedIC
Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Urothelial carcinoma trial updates from ASCO 2018
Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting urothelial carcinoma therapy updates from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in...
Author: VJOncology
Added: 08/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)
Dr. Daniel Goldstein reviews provocative and highly promising results with enfortumab, an inhibitor of nectin-4, as a treatment for advanced transitional cell carcinoma of the bladder.
Author: BeaconMedIC
Added: 08/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2018 Category: Cancer & Oncology Source Type: podcasts
Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (BMIC-048)
Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these results to those in breast cancer and raising que...
Author: BeaconMedIC
Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Could Immunotherapy Replace Neoadjuvant Chemo for Muscle-Invasive Transitional Cell Carcinoma? Highlights from ASCO 2018 (BMIC-047)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy instead of chemotherapy for muscle-invasive t...
Author: BeaconMedIC
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 28, 2018 Category: Cancer & Oncology Source Type: podcasts
which TKIs appear most effective in 1st line RCC
Primo N. Lara, Jr., MD, explains whether the TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable and which TKIs seem to be the most successful in 1st line renal cell carcinoma...
Author: obr
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
The convenience of oral TKIs influences treatment decisions
Primo N. Lara, Jr., MD, explains the convenience factor of oral TKIs influences decisions related to advanced renal cell carcinoma (RCC) treatment
Author: obr
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Trial updates in mRCC from ASCO: KEYNOTE-427, RESORT, E2810 & amp; IMmotion151
Exciting new data for metastatic renal cell carcinoma (mRCC) was presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. Here, Toni Choueiri, MD, of the Dana Far...
Author: VJOncology
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
